**The Assessment and Treatment of Antipsychotic Induced Akathisia**

Tamara Pringsheim MD1, David Gardner PhD2, Donald Addington MD3, Davide Martino MD PhD4, Francesca Morgante MD PhD5, Lucia Ricciardi MD PhD6, Norman Poole MD7, Gary Remington MD8, Mark Edwards MD9, Alan Carson MD10, and Thomas R. E. Barnes MD11

1Associate Professor, Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences 2Professor, Department of Psychiatry and Pharmacy, Dalhousie University

3Professor, Department of Psychiatry, University of Calgary

4Associate Professor, Department of Clinical Neurosciences, University of Calgary

5Senior Assistant Professor of Neurology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy and Institute of Molecular and Clinical Sciences, St George's University of London, London, United Kingdom

6Honorary Clinical Research Fellow, Institute of Cardiovascular and Cell Sciences, St George's University of London, London, UK

7Consultant Neuropsychiatrist, St George’s & South West London Mental Health NHS Trust; Visiting Lecturer, Department of Philosophy, King’s College London

8Departments of Psychiatry and Psychological Clinical Science, University of Toronto, Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto

9Professor, Department of Neurology, St Georges University of London

10Consultant Neuropsychiatrist and Honorary Reader, Division of Psychiatry, University of Edinburgh

11Emeritus Professor of Clinical Psychaitry, Department of Psychiatry, Imperial College London

Corresponding Author:

Tamara Pringsheim

Mathison Centre for Mental Health Research and Education

3280 Hospital Drive NW

Calgary AB T2N 4Z2

tmprings@ucalgary.ca

**Abstract**

Background: Akathisia is a common and distressing neuropsychiatric syndrome associated with antipsychotic medication that is characterized by subjective and objective psychomotor restlessness. The goal of this guideline is to provide clinicians with recommendations on the assessment and treatment of akathisia.

Methods: A systematic review of therapeutic studies of the treatment of antipsychotic-induced extrapyramidal symptoms was performed. Forty studies on the treatment of akathisia and four systematic reviews evaluating adverse effects of antipsychotics were used in the formulation of recommendations. Studies were rated for methodological quality using the American Academy of Neurology Risk of Bias Classification system. Overall level of evidence classifications and grades of recommendation were made using the Scottish Intercollegiate Guidelines Network framework.

Results: As a good practice point, clinicians should systematically assess akathisia with a validated scale prior to starting antipsychotics and during antipsychotic dosage titration. For the management of akathisia, there was adequate evidence to allow recommendations to be made regarding antipsychotic dose reduction, antipsychotic polypharmacy, switching antipsychotic medication, and the use of adjuvant medications including beta-blockers, anticholinergics, 5HT2A antagonists, benzodiazepines, and vitamin B6.

Conclusion: The treatment of antipsychotic-induced akathisia should be personalized, with consideration of antipsychotic dose reduction, cessation of antipsychotic polypharmacy, and switching to an antipsychotic medication with a perceived lower liability for akathisia, prior to the use of adjuvant medications. The choice of adjuvant medications should favour the more established treatments, with careful consideration of contraindications and side effects. Limitations in the evidence should be acknowledged and prompt cautious prescribing, particularly with respect to the duration of use of adjuvant medications.

**Introduction**

Akathisia, a term derived from the Greek for ‘inability to sit’1, refers to a neuropsychiatric syndrome characterized by subjective and objective psychomotor restlessness. Although recognised soon after the introduction of antipsychotic medication2, 3, it was largely overlooked for 30 years4, 5 until the clinical presentation was delineated in the 1980’s6-8. The core of the condition is a subjective experience of mental unease and dysphoria, characterised by a sense of restlessness that may sometimes drive impulsive behaviour9, 10. When the condition is severe, there is an irresistible urge to move around, partly to achieve some respite. Patients may complain of a mounting sense of tension when required to stand still, for example when waiting in line. The observable features include the inability to sit, stand or lie still. When sitting, the legs tend to swing, cross and uncross, or tramp up and down. When standing, there is a tendency for the body weight to shift from one foot to the other (‘marching on the spot’) or for the person to pace back and forth.

Akathisia usually occurs during the early days of treatment with antipsychotic medication, when it is considered as acute akathisia. But it can be, and often is, a persistent problem when not addressed; chronic akathisia is usually defined as the continuation of the signs and symptoms for more than 3 months. Akathisia may also arise following reduction of dosage or stopping antipsychotic medication11-13, when it is referred to as withdrawal akathisia, although it is generally considered to be indistinguishable phenomenologically from acute akathisia 7. The term ‘tardive akathisia’ has been inconsistently applied in the literature. It has been used to refer to akathisia that occurs late in the course of treatment, is exacerbated or provoked by antipsychotic dose reduction or withdrawal and improves at least temporarily when the dose is increased, pharmacological characteristics shared with tardive dyskinesia 7, 12. However, it has also been used to refer to late-onset akathisia occurring in the absence of any change in drug dose or type, or provoked by stopping anti-akathisia medication14 as well as persistent akathisia that is particularly disabling and often refractory to treatment.15

Where a patient exhibits the objective signs of akathisia in the absence of awareness of the typical subjective experience, this is sometimes called pseudoakathisia. However, it remains uncertain whether such a presentation reflects chronic akathisia where the patient is either unable to verbalise the subjective dysphoria or this component has faded over time, or whether it is a variant of tardive dyskinesia 16-18

Akathisia is one of the most common and most distressing motor syndromes associated with antipsychotic drug treatment. Its development can be a disincentive to medication acceptance and thus it can have an adverse effect on long-term treatment outcomes. Further, the signs and symptoms of akathisia can confound clinical assessment of the mental state. In clinical practice, the condition often goes unrecognized or misdiagnosed as psychotic agitation or excitement, restless legs syndrome, anxiety, substance intoxication/withdrawal or tardive dyskinesia 19-21. The extent to which akathisia is a risk factor for suicide22,23 remains uncertain, although it has been found to be associated with suicidality, in individuals with first-episode psychosis249, as well as the development of violent or aggressive behaviour25.

**Methods**

A systematic review of the literature was performed for therapeutic studies on the treatment of antipsychotic induced extrapyramidal symptoms. We searched Medline and CENTRAL in November 2016, using the search strategy in Appendix 1. We hand searched the Cochrane Library for systematic reviews on this topic, and searched for published guidelines on this topic as well, and included all references from these papers. Our Medline and CENTRAL search found 5053 abstracts which were reviewed independently by two researchers, and of which 250 were chosen for full text review. From the 9 identified Cochrane reviews on this topic26-34, American Academy of Neurology (AAN) guideline on tardive syndromes35, and the Canadian Alliance on Monitoring of Safety and Effectiveness of Antipsychotic (CAMESA) guideline on management of extrapyramidal symptoms36, we identified an additional 94 articles for full text review, bringing the total to 344 articles for full text review. Forty clinical studies pertaining to the treatment of akathisia and four systematic reviews evaluating adverse effects of antipsychotics from randomized controlled trials were used in the formulation of recommendations on the assessment and management of antipsychotic-induced akathisia. We included any type of therapeutic study, including case reports, case series, and controlled trials. If controlled trials were available for a specific therapeutic intervention, case reports and case series were not included in our analysis. Studies were rated for methodological quality using the American Academy of Neurology Risk of Bias Classification system. Each study was given a class rating of I, II, III or IV based on the fulfillment of these criteria (see Table 1). Rating of risk of bias and data extraction were performed by a single researcher and checked by a second researcher for accuracy. Discrepancies were resolved by discussion. Overall level of evidence classifications were made using the Scottish Intercollegiate Guidelines Network framework (see Table 2). For each therapeutic study that was included, the risk of bias, population, intervention, comparator, trial length, number of participants and main outcomes are described in full in Appendix 2, and summarized below with the recommendations. Initial recommendations were drafted by a team of researchers and then voted on by the entire panel for inclusion in the guideline. The grade of recommendations were made using the SIGN framework. Recommendation statements were formulated based on the evidence obtained from the systematic review, the magnitude of benefit associated with the intervention, the risk of harm, cost, availability, and variation in patient preference. Each recommendation required agreement by 80% of the panel for inclusion in the guideline. The panel consisted of movement disorders specialists, psychiatrists and psychopharmacologists with expertise in the therapeutic use of antipsychotic medication and the adverse effects associated with such medication.

**Recommendations**

**Assessment of akathisia**

Clinical examination procedures designed to identify and assess extrapyramidal side effects in people prescribed antipsychotic medication have been described37,38. The overall detection and management of antipsychotic-induced akathisia as well as its assessment prior to starting antipsychotic medication and during titration to a therapeutic dosage, may be improved by using a validated scale. The most widely-used rating scale for the measurement of akathisia symptoms is the Barnes Akathisia Rating Scale, which measures objective signs and subjective (awareness and distress) symptoms of akathisia, and includes a global assessment item, on which a score of 2 or more indicates the presence of akathisia 8. The instrument is easy to administer and score, with established reliability, validity and clinical utility 39-42. If an instrument assessing all types of extrapyramidal symptoms is preferred for use, the Extrapyramidal Symptom Rating Scale 43 includes one item on the symptoms of akathisia, one item assessing objective signs of akathisia, and a clinical global impression of severity of akathisia. The Extrapyramidal Rating Scale has been extensively deployed and has established inter-rater reliability43.

***Recommendation*** (Good Practice Point): Prior to starting antipsychotic medication and during antipsychotic dosage titration, clinicians should systematically assess the symptoms and signs of akathisia through the use of a validated scale. The use of such a scale can provide a reliable baseline measure for subsequent monitoring of akathisia.

**Antipsychotic Polypharmacy and Dose Reduction (Level of Evidence 3)**

Naturalistic studies of psychiatric inpatients have shown that acute akathisia develops within hours or days of initiation of antipsychotic treatment. The evidence suggests that the risk of akathisia is greater in patients prescribed antipsychotic medication for the first time, i.e. antipsychotic-naïve, or for whom antipsychotic drug dosage is rapidly escalated 6, 44, and that akathisia tends to improve following dose reduction. Prescribing more than one antipsychotic drug for patients is also a risk factor. A recent study of 372 community dwelling individuals with schizophrenia on stable antipsychotic medication treatment regimens for at least 4 weeks found an overall prevalence of akathisia of 18.5%45. In this community survey, polypharmacy with two first-generation antipsychotics was associated with the highest prevalence of akathisia at 40%, versus a prevalence of 21% in those on first-generation antipsychotic monotherapy. For those receiving second-generation antipsychotic monotherapy, the prevalence was 11%, while polypharmacy with two second-generation antipsychotics was associated with a prevalence of akathisia of 34%.

The Canadian Agency for Drugs and Technology in Health published optimal use recommendations for antipsychotic polypharmacy and high-dose treatment strategies in adolescents and adults with schizophrenia based on a systematic review of the literature and expert consensus46. This report recommended against the use of antipsychotic combination therapy and high-dose strategies, based on inadequate evidence of efficacy and evidence of harm (including higher rates of extrapyramidal symptoms) associated with these practices.

A randomized controlled trial addressed the risks and benefits of staying on antipsychotic polypharmacy or switching to monotherapy in adults with schizophrenia47. Outpatients taking two antipsychotics were randomized to stay on polypharmacy or switch to monotherapy by discontinuing one antipsychotic. After six months, 86% of those assigned to stay on polypharmacy were still taking both medications, while 69% of those assigned to switch to monotherapy remained on monotherapy. Most individuals who discontinued monotherapy resumed their original polypharmacy. Those switching to monotherapy lost weight, and had no worsening of symptom control or increase in hospitalization compared to those on polypharmacy.

***Recommendation*** (Grade D): To reduce the risk of developing acute akathisia, clinicians should seek to avoid rapid escalation of antipsychotic dosage.

***Recommendation*** (Grade D): Clinicians should consider dose reduction in patients with persistent akathisia on a stable dose of antipsychotic medication, taking into account the potential risk of clinical deterioration of the psychiatric disorder.

**Recommendation** (Grade D): When considering the risks and benefits of using combined antipsychotics in an individual patient, clinicians should take account of the increased risk of akathisia and inadequate evidence for clinical efficacy with such a strategy.

***Recommendation:* (Grade D)*:***  Where antipsychotic polypharmacy is being prescribed and there is persistent, clinically-significant akathisia, clinicians should attempt to achieve mono-antipsychotic therapy, by tapering and discontinuing one of the antipsychotic medications or switching to a different single antipsychotic, if this can be accomplished without clinical deterioration.

**Antipsychotic Switching (Level of Evidence 1-)**

To our knowledge, a systematic and comprehensive review comparing the liability for akathisia specifically across all antipsychotic medication trials has not been published. A number of reviews have analyzed akathisia risk in specific subsets of published studies. A systematic review and meta-analysis of head-to-head comparisons of antipsychotic medications for the treatment of schizophrenia published prior to 2009 48 found that aripiprazole produced more akathisia (as measured on the Barnes Akathisia Rating Scale) than olanzapine, and clozapine more than ziprasidone. Risperidone was associated with more akathisia than sertindole and ziprasidone. Haddad 49 performed a systematic review of head-to-head comparisons of antipsychotic medications for first-episode psychosis. Three trials comparing haloperidol with olanzapine, and two trials comparing haloperidol with olanzapine and risperidone demonstrated a significantly higher risk of treatment-emergent akathisia with haloperidol. Two trials comparing haloperidol with risperidone found significantly higher scores on the Extrapyramidal Symptom Rating Scale akathisia subscale with haloperidol. One trial comparing clozapine to chlorpromazine found akathisia was more frequent over one year of follow-up with chlorpromazine. A more recent systematic review comparing the incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone, including studies published prior to June 2014, found that the risk of akathisia was elevated for these newer antipsychotics compared with risperidone, olanzapine, ziprasidone and quetiapine 50. Compared with olanzapine, asenapine had an odds of akathisia of 2.23 (1.45-3.42), aripiprazole had an odds of akathisia of 1.49 (1.13-1.99) compared with risperidone, ziprasidone, and olanzapine, while lurasidone had an odds of 1.83 (1.27-2.63) relative to ziprasidone, risperidone, olanzapine and quetiapine.

***Recommendation***(Grade C):

For patients on continuing antipsychotic treatment who have persistent and clinically-significant akathisia symptoms, clinicians should consider switching to an agent with a perceived lower liability for extrapyramidal side effects, such as clozapine, olanzapine or quetiapine51. The Maudsley Prescribing Guidelines in Psychiatry52 identify a ‘very low’ liability for akathisia with aripiprazole, lurasidone and ziprasidone, while it has also been argued that a switch to iloperidone might be most favourable for patients exhibiting akathisia13

**Propranolol and Other Beta Blockers (Level of Evidence 1-)**

Propranolol, a nonselective beta-adrenergic antagonist, is the most studied treatment intervention for antipsychotic-induced akathisia. There are seven published trials comparing propranolol with placebo for the treatment of akathisia. These trials were published between 1986 and 2006, and risk of bias was low in two trials (Class II) 53, 54, and high (Class III) in five trials55-59. Most trials were conducted in individuals with schizophrenia and were of short duration, ranging from 2 to 12 days of propranolol treatment. In total, 194 individuals participated in these seven trials. The dose of propranolol ranged from 20 to 120 mg daily. Six of the seven trials reported improvement in akathisia in individuals receiving propranolol relative to placebo. The negative trial 57 consisted of treatment with propranolol for two days; subsequent trials 58, 59 found no difference between propranolol and placebo at two days, but a significant improvement relative to placebo at five days, suggesting that the short duration of the previous study may have resulted in the negative response. There were no reports of worsening psychosis associated with propranolol use.

Four studies have compared propranolol exclusively with another drug. None of these four studies used a non-inferiority design, and were rated at low (one class II study)60 or high (two class III and one class IV study) 61-63 risk of bias. Similar to the studies comparing propranolol to placebo, trials were of short duration, ranging from 1 to 7 days duration, and included a total of 88 participants. Doses of propranolol ranged from 40 to 120 mg daily. All trials reported benefit with propranolol from baseline to endpoint, as well as with the other agents studied (metoprolol, zolmitriptan, cyproheptadine), with the exception of benztropine, which showed no change in objective ratings of akathisia.

Metoprolol and nadolol have been evaluated for the treatment of akathisia in one trial each. Both of these studies were at high risk of bias (Class III), and included a small number of participants. Metoprolol and propranolol were not found to be different (no placebo control group)61, and there was no significant difference between nadolol and placebo in subjective or objective restlessness scores64.

If the treatment of akathisia requires the addition of a new medication (rather than dose lowering or antipsychotic switching), overall, propranolol has the most evidence to support its use. While published trials have methodological limitations, the overall body of evidence suggests some benefit with propranolol for subjective and objective symptoms of akathisia, as well as global ratings. Limitations of the current evidence include the short duration of all treatment trials, making it difficult to decide how long propranolol, if helpful, should be continued. Evidence to support the use of metoprolol is extremely limited and at high risk of bias. The limited evidence available for nadolol suggests it is no better than placebo. If propranolol is prescribed, clinicians should review its contraindications before starting treatment and monitor blood pressure and heart rate in the supine and standing position, as propranolol can cause hypotension and bradycardia, which can be exacerbated by antipsychotic medications. Treatment should be started at low dose (e.g., 10 mg twice daily), and gradually titrated based on clinical response and adverse effects. For patients requiring higher doses, a sustained release formulation is available (60 mg capsules or higher), which may reduce dosing frequency to daily or twice daily. A minimum treatment duration of five days is suggested to evaluate efficacy, unless intolerable adverse effects occur.

**Recommendation** (Grade B): If adjunctive medication is required for the treatment of akathisia, clinicians should consider a trial of propranolol as a first-choice option, after reviewing contraindications and associated precautions on an individual patient basis.

**Anticholinergic medications**

*Benztropine (Level of Evidence 1-)*

There are two trials of the anticholinergic benztropine versus placebo for the treatment of antipsychotic-induced akathisia 55, 65. Both trials are at high risk of bias (class III). One trial evaluated oral benztropine at an unusually high dose of 6 mg for 12 days in 28 participants, most of whom were diagnosed with schizophrenia (Adler 1993). Benztropine treatment resulted in significant improvement in akathisia compared to placebo. The other trial evaluated intravenous benztropine at a dose of 2 mg in 6 individuals with schizophrenia or bipolar disorder. All patients received a single injection and were evaluated up to 60 minutes after the injection. Global and subjective rating of akathisia were significantly lower with benztropine than placebo, while objective ratings were not.

Two trials have compared benztropine to other drugs for the treatment of antipsychotic-induced akathisia 66, 67. Both trials are at high risk of bias (class III and IV), and neither employed a non-inferiority design. The Class IV trial of 17 individuals treated for 2 to 5 days with up to 4 mg of benztropine found that in comparison to propranolol66, benztropine was less effective, with no change in objective ratings of akathisia and only a small decrease in subjective ratings. Significant worsening in tests of recent memory were associated with benztropine use. The Class III trial 67 of 44 individuals treated for 28 days with up to 8 mg of benztropine reported a significant improvement in akathisia from baseline to endpoint, which was similar in magnitude to amantadine.

*Biperiden (Level of Evidence 1-)*

Two trials have compared biperiden to placebo 68, 69 for the treatment of antipsychotic-induced akathisia. Both trials were rated at high risk of bias (Class III). One trial 69 compared up to 18 mg per day of oral biperiden to placebo for 4 weeks in 15 psychiatric in-patients with antipsychotic-induced akathisia. Compared to placebo, treatment with biperiden resulted in a significant decrease in akathisia scores. The other trial 68 compared intramuscular injection of 2.5 mg of biperiden (up to three times, every two hours) to placebo for six hours in 30 individuals. A decline in akathisia scores on all Barnes Akathisia Rating Scale items occurred with time, but was not different between treatment groups.

One trial at high risk of bias (Class IV) compared a single injection of intravenous biperiden to intramuscular biperiden in 23 individuals requiring rapid relief of antipsychotic-induced akathisia 70. Intravenous administration of biperiden resulted in more rapid relief of symptoms and amelioration of akathisia for at least four hours in 17 individuals. Side effects included confusion, drowsiness, dizziness, palpitations and dry mouth.

The evidence to support the use of the anticholinergic medications benztropine and biperiden for the treatment of antipsychotic-induced akathisia is extremely limited and at high risk of bias, with inconsistent findings among trials regarding efficacy. Doses used exceeded those currently recommended. The adverse effects of anticholinergic medications, including memory impairment, are of great concern in patients with schizophrenia. There are some data to suggest that anticholinergic medications may be preferentially helpful in patients with akathisia and co-existing parkinsonism. A naturalistic study of 20 patients with akathisia treated with anticholinergic medications found that only those with clinically significant co-existing parkinsonism experienced amelioration of their akathisia symptoms with anticholinergic medication 6. Further, treatment trials of anticholinergic medications for akathisia that have included a higher proportion of individuals with co-existing parkinsonism have reported greater benefit with therapy 71.

***Recommendation*** (Grade B): Considering the limitations of the available evidence on anticholinergic medications and the risk of cognitive and anticholinergic adverse effects with these drugs, anticholinergic medications should not be routinely used for the treatment of akathisia.

***5-HT2A antagonists***

Several medications that share in common potent antagonistic activity at 5-HT2A receptors have been assessed for their anti-akathisic effects, based on observations that antipsychotic agents with high 5-HT2a antagonist activity relative to D2 antagonistic activity is associated with reduced risk for EPS72. Studied medications in this class include mianserin, mirtazapine, trazadone and cyproheptadine. Mianserin and mirtazapine are noradrenergic and specific serotonergic antidepressants that are highly similar in chemical structure and receptor affinity. Mianserin is now uncommonly used in clinical practice. Relative to their other pharmacological effects, they both share very high binding affinity to histamine-1 receptors.

*Mianserin (Level of Evidence 1-)*

There are two class II studies (low risk of bias) comparing mianserin to placebo for the treatment of antipsychotic-induced akathisia in individuals with schizophrenia or schizoaffective disorder 73, 74. Both trials evaluated mianserin at a dose of 15 mg, for a treatment period of 5 days, in a total of 90 individuals. Significant improvement in the Barnes Akathisia Rating Scale subjective, distress, and global subscales with mianserin relative to placebo was seen in both studies, while improvement in the objective subscale was only demonstrated in one of the two studies. The most common adverse effect associated with mianserin use was sedation.

*Mirtazapine (Level of Evidence 1-)*

There are two trials comparing mirtazapine to placebo (and also to propranolol in one trial) for the treatment of antipsychotic-induced akathisia in individuals with schizophrenia 54, 75. Both trials used mirtazapine at a dose of 15 mg, and evaluated response after 5 or 7 days. Trials were rated at low 54 and high 75 risk of bias. Between the two studies, 116 individuals participated in the trials. Both studies reported significant improvement in the global subscale of the Barnes Akathisia Rating Scale with mirtazapine relative to placebo. Significant improvement in the objective subscale was also noted in one study 75, while the other study demonstrated a gradual improvement in the objective, subjective, and distress subscales that was not statistically significant 54. In the more recent study, propranolol was used as an internal control; the study was not powered to compare mirtazapine and propranolol statistically. Improvements were very similar between the two active medications. No aggravation of psychotic symptoms was reported, and the most common side effect associated with mirtazapine use was sedation.

*Trazodone (Level of Evidence 1-)*

There is one published study of trazodone versus placebo 76 for the treatment of antipsychotic-induced akathisia which was rated at low risk of bias (Class II). This trial included 13 inpatients with schizophrenia or schizoaffective disorder who were treated for three days with trazodone 100 mg and placebo in a crossover study. The trial reported significant improvement with trazodone compared to placebo in all subscales of the Barnes Akathisia Rating Scale. No worsening of psychosis or other adverse effects were associated with trazodone treatment.

*Cyproheptadine (Level of Evidence 1-)*

There is one Class II trial comparing cyproheptadine to propranolol60 in 30 hospitalized adults with schizophrenia. Participants were treated with cyproheptadine 16 mg per day or propranolol 80 mg per day for 4 days. Significant improvement was observed from baseline to endpoint in the total score on the Barnes Akathisia Scale in both cyproheptadine and propranolol treated participants, with no difference between groups. Adverse effects of treatment were not assessed.

As a class, there is limited evidence to support the use of 5HT2A antagonists for the treatment of akathisia, with the two trials of mirtazapine including the greatest number of participants. All trials were of short duration (longest trial 7 days).

**Recommendation** (Grade B): When propranolol is contraindicated, ineffective, or not tolerated and long-term pharmacological management of akathisia is anticipated, a trial of a mirtazapine may be considered.

**Benzodiazepines: clonazepam (Level of Evidence 1-)**

There are two published trials comparing clonazepam to placebo for the treatment of antipsychotic-induced akathisia 77, 78. Both trials were conducted in individuals with psychosis, and were rated at high risk of bias (Class III). Both trials were small, including a total of 27 participants overall, and treatment duration ranged from 7 to 14 days. Clonazepam dose ranged from 0.5 to 2.5 mg daily. Both trials reported significant improvement in akathisia symptoms relative to placebo. No major adverse effects were reported in either trial, with only one patient having mild drowsiness in one of the studies.

The evidence to support the use of clonazepam for the treatment of antipsychotic-induced akathisia is limited and at high risk of bias. Both studies however report benefits with treatment and that the treatment is well tolerated. Doses of clonazepam should be started at 0.5 mg, and slowly titrated based on effect, with the goal of using the lowest effective dose. As controlled trials were of short duration, and long-term benzodiazepines use is associated with tolerance, risk of dependence and cognitive side effects, clinicians should consider gradual tapering of the medication after symptoms stabilize.

***Recommendation*** (Grade B): Clonazepam may be considered as a short-term therapy option for the treatment of antipsychotic-induced akathisia.

**Vitamin B6 (Level of Evidence 1+)**

There are two published trials comparing vitamin B6 with placebo for the treatment of antipsychotic-induced akathisia 73,79. Both trials were performed in inpatients with schizophrenia or schizoaffective disorder, and were rated at low risk of bias (Class II). In total, 80 individuals participated in these two trials, which were both conducted for a period of five days, using a dose of 600 mg or 1200 mg daily. Both trials reported significant improvement with vitamin B6 relative to placebo on the Barnes Akathisia Rating Scale subjective and global subscales, but not on the objective subscale. A significantly greater proportion of vitamin B6 treated individuals had a reduction of at least two points on the global subscale in both studies. Adverse effects of treatment were not formally studied or reported in either study.

The evidence to support the use of vitamin B6 is at low risk of bias, but limited to two short-term studies with relatively small sample sizes. Chronic administration (more than 12 months) of oral vitamin B6 in amounts exceeding 1000 mg per day can cause a severe and progressive sensory neuropathy80, 81.

***Recommendation*** (Grade A): In patients failing to respond to alternative treatments for persistent antipsychotic-induced akathisia, short-term treatment with vitamin B6 may be considered. Clinicians prescribing vitamin B6 should exercise caution, given the limitation of the trial evidence (small sample size, short duration) and the ability of this treatment to cause an irreversible and severe neuropathy when used long term.

**Other medications**

A number of other medications have been assessed as potential treatments for antipsychotic-induced akathisia. While some results are promising, the current evidence available on the potential risks and benefits for these agents as treatments for akathisia is insufficient to allow for clear practice recommendations.Medications assessed include amantadine (one Class III trial versus benztropine)67, apomorphine (one Class III trial versus placebo)82, zolmitriptan (one Class III trial versus propranolol)62, clonidine (two class IV studies)63, 83, gabapentin (one Class IV study)83, and pregabalin (one Class IV study)85. The results of these trials are described in the Appendix.

**Conclusion**

The treatment of antipsychotic-induced akathisia should be personalized, incorporating thoughtful evaluation of a patient’s history of therapeutic response to medication and the adverse effects experienced. The initial approach to treatment should be to consider antipsychotic dose reduction, cessation of antipsychotic polypharmacy, and switching to an antipsychotic with a perceived lower liability for akathisia, before the use of any additional medication. However, such strategies are not without hazard, and there should be clinical concern around reduction to a sub-therapeutic dose when reducing the dosage and possible destabilization of the illness when switching antipsychotic medication. Further, it could be argued that the relative liability of individual antipsychotic medications for akathisia has not yet been reliably established.

The therapeutic options for akathisia are limited 10, 71. The evidence supporting the most commonly used pharmacological interventions, such as switching to an antipsychotic with a perceived lower liability for the condition, or prescribing a beta-adrenergic blocker or antihistaminic/anticholinergic agent, remains limited. Some of the treatment trials in acute akathisia were published several decades ago and not all used validated scales for the measurement of the condition. Neverthless, the choice of intervention should probably favour the more established treatments, with careful consideration of any contraindications to use and potential side effects. The limitations of the evidence for risk-benefit should be acknowledged and prompt caution, particularly with respect to the duration of use of concomitant medication.

Further large scale, randomized controlled trials are needed to test potential treatments for antipsychotic-induced akathisia and thus improve the evidence base and expand the therapeutic options. For example, given the success of both gabapentin and pregabalin in the treatment of Restless Legs Syndrome (RLS)86 and similarities between RLS and akathisia, trials with these agents may be worthwhile. In the meantime, akathisia currently remains a frequent adverse effect of antipsychotic use, and clinicians should strive to prescribe antipsychotic medication judiciously and remain vigilant in monitoring for the symptoms and signs of the condition in their patients.

**Funding**

No funding was received for this manuscript.

**Table 1. American Academy of Neurology Risk of Bias Classification system**

|  |
| --- |
| Class I  |
| Randomized controlled clinical trial (RCT) in a representative populationTriple masked studies (i.e. the patient, treating provider and outcome assessors are unaware of treatment assignment)Relevant baseline characteristics of treatment groups (or treatment order groups for cross-over trials) are presented and substantially equivalent between treatment groups, or there is appropriate statistical adjustment for differencesAdditional Class I criteria:a. Concealed allocationb. No more than two primary outcomes specifiedc. Exclusion and inclusion criteria clearly definedd. Adequate accounting of dropouts (with at least 80% of participants completing the study) and crossovers e. For non-inferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required\*:i. The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or non-inferiorityii. The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standardtreatment (e.g., for a drug, the mode of administration, dose, and dosage adjustments are similar to those previously shown to be effective)iii. The inclusion and exclusion criteria for participant selection and the outcomes of participants on the standard treatment are comparable with those of previous studies establishing efficacy of the standard treatmentiv. The interpretation of the study results is based on a per-protocol analysis that accounts for dropouts or crossoversf. For crossover trials, both period and carryover effects are examined and statistical adjustments performed, if appropriate |
| Class II |
| RCT that lacks one or two Class I criteria a–e (see above)Cohort studies employing methods that successfully match treatment groups on relevant baseline characteristics (e.g., propensity score matching) meeting Class I criteria b–e (see above) Randomized crossover trial missing one of the following two criteria:a. Period and carryover effects describedb. Baseline characteristics of treatment order groups presentedAll relevant baseline characteristics are presented and substantially equivalent across treatment groups (or treatment order groups for crossover trials, or there is appropriate statistical adjustment for differencesMasked or objective\*\* outcome assessment  |
| Class III |
| Controlled studies (including studies with external controls such as well-defined natural history controls)Crossover trial missing both of the following two criteria:a. Period and carryover effects b. Presentation of baseline characteristics A description of major confounding differences between treatment groups that could affect outcome\*\*Outcome assessment performed by someone who is not a member of the treatment team |
| Class IV |
| Studies not meeting Class I, II or III criteria. |

\*Numbers i–iii in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III

\*\*Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer’s (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data)

**Table 2 Scottish Intercollegiate Guidelines Network framework**

|  |
| --- |
| **LEVELS OF EVIDENCE**1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias1 - Meta-analyses, systematic reviews, or RCTs with a high risk of bias2++ High quality systematic reviews of case control or cohort studies, or High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal2+ Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal2 - Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal3 Non-analytic studies, e.g. case reports, case series4 Expert opinion |
| **GRADES OF RECOMMENDATION** Note: The grade of recommendation relates to the strength of the evidence on which the recommendation is based. It does not reflect the clinical importance of the recommendation. |
| **A** At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results  |
| **B** A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; *or* Extrapolated evidence from studies rated as 1++ or 1+  |
| **C** A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; *or* Extrapolated evidence from studies rated as 2++ |
| **D** Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+  |
| **GOOD PRACTICE POINTS** Recommended best practice based on the clinical experience of the guideline development group  |

**References**

1. Haskovec L. L'akathisie. *Revue Neurologique*. 1901; 9: 1107-9.

2. Sigwald J, Grossiord A and P. D. Le traitement de la maladie de Parkinson et des manifestations extrapyramidalles par Ie diethylaminoethyl n-thiophyenylamine (2987 RP): resultats d’une annre d’application. *Revue Neurologique*. 1947; 79: 683-7.

3. Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. *Am J Psychiatry*. 1960; 117: 152-3.

4. Raskin DE. Akathisia: a side effect to be remembered. *Am J Psychiatry*. 1972; 129: 345-7.

5. Van Putten T. The many faces of akathisia. *Compr Psychiatry*. 1975; 16: 43-7.

6. Braude WM, Barnes TR and Gore SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. *Br J Psychiatry*. 1983; 143: 139-50.

7. Barnes TR and Braude WM. Akathisia variants and tardive dyskinesia. *Arch Gen Psychiatry*. 1985; 42: 874-8.

8. Barnes TR. A rating scale for drug-induced akathisia. *Br J Psychiatry*. 1989; 154: 672-6.

9. Raja M, Azzoni A and Lubich L. Aggressive and violent behavior in a population of psychiatric inpatients. *Soc Psychiatry Psychiatr Epidemiol*. 1997; 32: 428-34.

10. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. *Br J Psychiatry*. 2010; 196: 89-91.

11. Dufresne RL and Wagner RL. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia. *J Clin Psychiatry*. 1988; 49: 435-8.

12. Lang AE. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. *Mov Disord.* 1994; 9: 188-92.

13. Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R, Kühn KU, Volz HP, Riedel M. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. *CNS Drugs*. 2013; 27: 545-7212.

14. Sachdev, P. Research diagnostic criteria for drug-induced akathisia: Conceptualization, rationale, and proposal. *Psychopharmacology*, 1994; 114: 181-186.

15. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. *Movement Disorders* 1989;4:157-175

16. Munetz MR and Cornes CL. Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. *Compr Psychiatry*. 1982; 23: 345-52.

17. Barnes TR. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. *Psychiatr Dev*. 1987; 5: 301-19.

18. Havaki-Kontaxaki BJ, Kontaxakis VP and Christodoulou GN. Prevalence and characteristics of patients with pseudoakathisia. *Eur Neuropsychopharmacol*. 2000; 10: 333-6.

19. Weiden PJ, Mann JJ, Haas GL, Mattson M and Frances A. Clinical nonrecognition of antipsychotic-induced movement disorders: a cautionary study. *Am J Psychiatry*. 1987; 144: 1148-53.

20. Van Putten T and Marder SR. Behavioral toxicity of antipsychotic drugs. *J Clin Psychiatry*. 1987; 48 Suppl: 13-9.

21. Barnes TR. Neuromuscular effects of antipsychotics: akathisia. In: Kane JM and Lieberman JA, (eds.). *Adverse Effects of Psychotropic Drugs*. Guidford Press, 1992.

22. Margolese HC, Chouinard G, Walters Larach V, Beauclair L. Relationship between antipsychotic-induced alathisia and tardive dyskinesiai and suicidality in schizophrenia: impact of clozapine and olanzapine. *Acta Psychiat Belg* 2001; 101: 128-144.

23. Reutfors J, Clapham E, Bahmanyar S, Brandt L, Jönsson EG, Ekbom A, Bodén R, Ösby U. Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study.v*Hum Psychopharmacol*. 2016; 31: 341-5.

24. Seemuller F, Schennach R, Mayr A, et al. Akathisia and suicidal ideation in first-episode schizophrenia. *J Clin Psychopharmacol*. 2012; 32: 694-8.

25. Leong GB and Silva JA. Neuroleptic-Induced akathisia and voilence: a review. *Journal of Forensic Sciences*. 2003; 48: 187-9.

26. Lima AR, Bacalcthuk J, Barnes TR and Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev*. 2004: CD001946.

27. Lima AR, Soares-Weiser K, Bacaltchuk J and Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev*. 2002: CD001950.

28. Lima AR, Weiser KV, Bacaltchuk J and Barnes TR. Anticholinergics for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev*. 2004: CD003727.

29. Rathbone J and Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev*. 2006: CD003727.

30. Alabed S, Latifeh Y, Mohammad HA and Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev*. 2011: CD000203.

31. El-Sayeh HG, Lyra da Silva JP, Rathbone J and Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev*. 2006: CD000458.

32. Bhoopathi PS and Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev*. 2006: CD000205.

33. Soares-Weiser K, Maayan N and McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev*. 2011: CD000209.

34. Soares-Weiser K and Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. *Cochrane Database Syst Rev*. 2006: CD000459.

35. Bhidayasiri R, Fahn S, Weiner W, Gronseth G, Sullivan KL and Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes. *Neurology*. 2013; 81.

36. Pringsheim T, Doja A, Belanger S and Patten S. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. *Paediatrics and Child Health*. 2011; 16: 590-8.

37. Gervin M, Barnes TRE. Assessment of drug-related movement disorders in schizophrenia. *Advances in Psychiatric Treatment*. 2000; 6: 332-343.

38. Cunningham Owens DG. A Guide to the Extrapyramidal Side–Effects of Antipsychotic Drugs. Chapter 10. Cambridge University Press, 1999.

39. Sweet RA, DeSensi EG and Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. *J Neuropsychiatry Clin Neurosci*. 1993; 5: 56-60.

40. Loonen AJ, Doorschot CH, van Hemert DA, Oostelbos MC and Sijben AE. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. *Int J Neuropsychopharmcol*. 2000; 3: 285-96.

41. Barnes TR. The Barnes Akathisia Rating Scale - Revisited. *Journal of Psychopharmacology*. 2003; 17: 365-70.

42. Janno S, Holi MM, Tuisku K and Wahlbeck K. Actometry and Barnes Akathisia Rating Scale in antipsychotic-induced akathisia. *Eur Neuropsychopharmacol*. 2005; 15: 39-41.

43. Chouinard G and Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). *Schizophr Res*. 2005; 76: 247-65.

44. Miller CH, Hummer M, Oberbauer H, Kurzhaler I, DeCol C and Fleischhacker WW. Risk factors for the development of antipsychotic induced akathisia. *Eur Neuropsychopharmacol*. 1997; 7.

45. Berna F, Misdrahi D, Boyer L, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. *Schizophr Res*. 2015; 169: 255-61.

46. CADTH. Optimal Use Report: Optimal use recommendations for atypical antipsychotics: combination and high-dose treatment strategies in adolescents and adults with schizophrenia.1: (2011).

47. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. *Am J Psychiatry*. 2011; 168: 702-8.

48. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. *Schizophrenia Bulletin*. 2012; 38: 167-77.

49. Haddad PM, Das A, Keyhani S and Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. *J Psychopharmacol*. 2012; 26: 15-26.

50. Thomas JE, Caballero J and Harrington CA. The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. *Current Neuropharmacology*. 2015; 13: 681-91.

51. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet.* 2013; 382: 951-62.

52. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 12th Edition. Wiley Blackwell, 2015.

53. Adler L, Angrist B, Peselow E, Corwin J, Maslansky R and Rotrosen J. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. *Br J Psychiatry*. 1986; 149: 42-5.

54. Poyurovsky M, Pashinian A, Weizman R, Fuchs C and Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. *Biol Psychiatry*. 2006; 59: 1071-7.

55. Adler LA, Peselow E, Rosenthal M and Angrist B. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. *Psychopharmacol Bull*. 1993; 29: 283-6.

56. Dumon JP, Catteau J, Lanvin F and Dupuis BA. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. *Am J Psychiatry*. 1992; 149: 647-50.

57. Irwin M, Sullivan G and Van Putten T. Propranolol as a primary treatment of neuroleptic-induced akathisia. *Hillside J Clin Psychiatry*. 1988; 10: 244-50.

58. Kramer MS, Gorkin R and DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. *Hillside J Clin Psychiatry*. 1989; 11: 107-19.

59. Kramer MS, Gorkin RA, DiJohnson C and Sheves P. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study. *Biol Psychiatry*. 1988; 24: 823-7.

60. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. *J Clin Psychopharmacol*. 2001; 21: 612-5.

61. Adler LA, Angrist B and Rotrosen J. Metoprolol versus propranolol. *Biol Psychiatry*. 1990; 27: 673-5.

62. Avital A, Gross-Isseroff R, Stryjer R, Hermesh H, Weizman A and Shiloh R. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. *Eur Neuropsychopharmacol*. 2009; 19: 476-82.

63. Adler L, Angrist B, Peselow E, Corwin J and Rotrosen J. Noradrenergic mechanisms in akathisia: treatment with propranolol and clonidine. *Psychopharmacol Bull*. 1987; 23: 21-5.

64. Wells BG, Cold JA, Marken PA, et al. A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. *J Clin Psychiatry*. 1991; 52: 255-60.

65. Sachdev P and Loneragan C. Intravenous benztropine and propranolol challenges in acute neuroleptic-induced akathisia. *Clin Neuropharmacol*. 1993; 16: 324-31.

66. Adler L, Reiter S, Corwin J, Hemdal P, Angrist B and Rotrosen J. Differential effects of propranolol and benztropine in patients with neuroleptic-induced akathisia. *Psychopharmacol Bull*. 1987; 23: 519-21.

67. DiMascio A, Bernardo DL, Greenblatt DJ and Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. *Arch Gen Psychiatry*. 1976; 33: 599-602.

68. Baskak B, Atbasoglu EC, Ozguven HD, Saka MC and Gogus AK. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol*. 2007; 27: 289-94.

69. Friis T, Christensen TR and Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. *Acta Psychiatr Scand*. 1983; 67: 178-87.

70. Hirose S and Ashby CR. Intravenous biperiden in akathisia: an open pilot study. *International Journal of Psychiatry in Medicine*. 2000; 30: 185-94.

71. Miller CH and Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. *Drug Saf*. 2000; 22: 73-81.

72. Poyurovsky M and Weizman A. Treatment of Antipsychotic-Related Akathisia Revisited: The Role of Serotonin 2A Receptor Antagonists. *J Clin Psychopharmacol*. 2015; 35: 711-4.

73. Miodownik C, Lerner V, Statsenko N, et al. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. *Clin Neuropharmacol*. 2006; 29: 68-72.

74. Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M and Weizman A. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. *Br J Psychiatry*. 1999; 174: 238-42.

75. Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R and Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. *J Clin Psychopharmacol*. 2003; 23: 305-8.

76. Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A and Spivak B. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. *Clin Neuropharmacol*. 2010; 33: 219-22.

77. Kutcher S, Williamson P, MacKenzie S, Marton P and Ehrlich M. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. *J Clin Psychopharmacol*. 1989; 9: 403-6.

78. Pujalte D, Bottai T, Hue B, et al. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. *Clin Neuropharmacol*. 1994; 17: 236-42.

79. Lerner V, Bergman J, Statsenko N and Miodownik C. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2004; 65: 1550-4.

80. Bendich A and Cohen M. Vitamin B6 safety issues. *Annals of the New York Academy of Sciences*. 1990; 585: 321-30.

81. Perry TA, Weerasuriya A, Mouton PR, Holloway HW and Greig NH. Pyridoxine-induced neurotoxicity in rats: a stereological quantification o the sensory neuropathy. *Experimental Neurology*. 2004; 190: 133-44.

82. Sachdev P and Loneragan C. Low-dose apomorphine challenge in tardive akathisia. *Neurology*. 1993; 43: 544-7.

83. Zubenko GS, Cohen BM, Lipinski JF, Jr. and Jonas JM. Use of clonidine in treating neuroleptic-induced akathisia. *Psychiatry Res*. 1984; 13: 253-9.

84. Pfeffer G, Chouinard G and Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. *Int Clin Psychopharmacol*. 2005; 20: 179-81.

85. De Berardis D, Serroni N, Moschetta FS, Martinotti G and Di Giannantonio M. Reversal of aripiprazole induced tardive akathisia by addition of pregabalin. *J Neuropsychiatry Clin Neurosci*. 2013; 25: E9-E10.

86. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2016; 87: 2583-93.